Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
Ensysce Biosciences Inc (NASDAQ: ENSC) is a clinical-stage pharmaceutical innovator developing safer opioid therapies through its patented TAAP and MPAR technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's progress in addressing prescription drug abuse.
Access real-time information about clinical trial milestones, regulatory submissions, and strategic partnerships. Our curated collection features press releases covering product development breakthroughs, intellectual property updates, and operational developments in pain management solutions.
Key content includes updates on abuse-deterrent formulation testing, FDA communication statuses, manufacturing collaborations, and financial performance reports. All materials maintain strict compliance with financial disclosure regulations while emphasizing patient safety advancements.
Bookmark this page for streamlined tracking of ENSC's mission to transform opioid therapy through biochemical innovation and rigorous clinical validation. Check regularly for verified updates directly from corporate communications and authorized news sources.
Ensysce Biosciences (NASDAQ:ENSC) released video highlights from its PAINWeek 2025 symposium titled "Pain Management, RE-Invented: A New Era for Analgesia", held in Las Vegas on September 3, 2025. The symposium featured medical and scientific leaders discussing challenges in pain treatment and Ensysce's proprietary platforms TAAP™ and MPAR®, which aim to reduce opioid misuse and overdose while preserving analgesia. Video highlights with expert commentary and real-world perspectives are available on the Ensysce Media/Science Center at www.ensysce.com.
The company said it continues advancing its portfolio toward commercialization with the goal of safer severe-pain management.
Ensysce Biosciences (NASDAQ:ENSC) hosted a well-attended symposium titled "Pain Management, RE-Invented: A New Era for Analgesia" at PAINWeek 2025 in Las Vegas. The symposium, which drew approximately 400 attendees, featured presentations from leading pain medicine experts highlighting the company's innovative TAAP™ and MPAR® technologies.
The event showcased Ensysce's approach to developing safer opioids, featuring their lead candidate PF614. The technology uniquely uses the body's chemistry to activate pain relief with proper dosing while preventing overdose. Dr. William Schmidt presented data on PF614 and outlined plans for an upcoming Phase 3 trial in acute post-surgical pain.
Ensysce Biosciences (NASDAQ:ENSC) announced that Chief Commercial Officer Geoff Birkett will chair the Fierce New Product Planning Summit 2025, scheduled for September 8-11, 2025, in Philadelphia. Birkett will deliver opening remarks and present a case study on successful product launches.
The summit focuses on helping product planning teams make informed, value-based decisions for commercial success. At Ensysce, Birkett is leading the launch preparations for PF614, the company's first-in-class analgesic designed to combat severe pain while reducing abuse and overdose risks.
Birkett brings extensive experience from leadership roles at Eli Lilly, Lundbeck, and AstraZeneca, where he successfully launched several groundbreaking medicines in pain, addiction, and neuroscience.
Ensysce Biosciences (NASDAQ:ENSC) reported significant progress in Q2 2025 for its innovative opioid therapy programs. The company initiated a pivotal Phase 3 trial for PF614, its lead candidate for severe pain with built-in abuse deterrence. Additionally, Ensysce completed enrollment for Part 2 of the PF614-MPAR-102 study, advancing its overdose protection program.
Key financial highlights include a cash position of $2.2 million as of June 30, 2025, receipt of a $5.3 million NIDA grant installment, and R&D expenses of $1.9 million. The company reported a net loss of $1.7 million for Q2 2025, an improvement from the $2.0 million loss in Q2 2024.
The company's pipeline includes PF614 (TAAP™ technology) and PF614-MPAR (combining TAAP™ and MPAR® technologies), both designed to provide safer opioid therapies. Ensysce also advanced its OUD program with PF9001 as the lead candidate for opioid use disorder treatment.
Ensysce Biosciences (NASDAQ:ENSC) reported positive feedback from the FDA regarding PF614-MPAR, their breakthrough opioid analgesic with built-in overdose protection. The July 23, 2025 FDA meeting focused on achieving overdose protection labeling and confirmed eligibility for a streamlined 505(b)(2) regulatory pathway.
PF614-MPAR, which has received FDA's Breakthrough Therapy designation, utilizes Ensysce's proprietary TAAP™ and MPAR® technologies to maintain pain relief while automatically activating overdose protection if prescribed doses are exceeded. The development is supported by NIDA grants through May 2027.
Ensysce Biosciences (NASDAQ:ENSC) has launched its pivotal Phase 3 study of PF614, a next-generation opioid designed for severe pain management with built-in abuse and overdose protection. The study, designated PF614-301, will evaluate the drug's efficacy and safety in treating moderate to severe pain following abdominoplasty.
The company has partnered with Rho, Inc., a clinical research organization with extensive CNS and pain study expertise, having managed over 90 neurology trials across 840 sites in the past five years. The study aims to demonstrate PF614's ability to provide effective post-surgical pain relief while offering a safer alternative to conventional opioids.
Ensysce Biosciences (NASDAQ:ENSC) has announced full enrollment of Part 2 in their PF614-MPAR-102 clinical study, focusing on evaluating food effects on their MPAR overdose protection technology. The study is supported by a three-year NIDA grant extending through May 2027.
PF614-MPAR, which has received FDA Breakthrough Therapy designation, combines Ensysce's proprietary TAAP™ and MPAR® technologies to provide pain relief with built-in overdose protection. The technology is designed to maintain therapeutic efficacy while preventing overdose when doses exceed prescribed amounts.